

Listing of Claims:

Claims 1-71 (canceled)

Claim 72 (previously presented) A method of treating or preventing an inflammation related cardiovascular disorder in a subject in need of such treatment or prevention, comprising administering to said subject a therapeutically effective amount of an epoxy-steroidal aldosterone receptor antagonist compound that produces no **substantial significant** diuretic or anti-hypertensive effect in the subject.

Claim 73 (previously presented) The method of claim 72 wherein said cardiovascular disorder is selected from the group consisting of: coronary artery disease; aneurysm; arteriosclerosis; atherosclerosis; myocardial infarction; embolism; stroke; thrombosis; angina; vascular plaque inflammation; vascular plaque rupture; Kawasaki disease; and calcification.

Claim 74 (previously presented) The method of claim 73 wherein said cardiovascular disorder is myocardial infarction.

Claim 75 (previously presented) The method of claim 72 wherein said epoxy-steroidal compound is selected from the group consisting of:
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, methyl ester, (7 α 11 α ,17 α)- (eplerenone);
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-dimethyl ester, (7 α ,11 α , 17 α)-;
3'H-cyclopropa[6,7] pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, (6 β ,7 β ,11 β ,17 β)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 7-(1-methylethyl) ester, monopotassium salt, (7 α ,11 α ,17 α)-;

Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, ($7\alpha,11\alpha,17\alpha$)-;
3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, ($6\alpha,7\alpha,11\alpha$)-;
3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, ($6\alpha,7\alpha,11\alpha,17\alpha$)-;
3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, ($6\alpha,7\alpha,11\alpha,17\alpha$)-;
3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, ($6\alpha,7\alpha,11\alpha,17\alpha$)-;
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, ethyl ester, ($7\alpha,11\alpha,17\alpha$)-; and
Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, γ -lactone, 1-methylethyl ester, ($7\alpha,11\alpha,17\alpha$)-.

Claim 76 (previously presented) The method of Claim 75 wherein said epoxy-steroidal aldosterone receptor antagonist compound is eplerenone.

Claim 77 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-dimethyl ester, ($7\alpha,11\alpha,17\alpha$)-.

Claim 78 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, γ -lactone, ($6\beta,7\beta,11\beta,17\beta$)-.

Claim 79 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo, 7-(1-methylethyl) ester, monopotassium salt, ($7\alpha,11\alpha,17\alpha$)-.

Claim 80 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, 7-methyl ester, monopotassium salt, ($7\alpha,11\alpha,17\alpha$)-.

Claim 81 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-1,4,6-triene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, (-lactone, ($6\alpha,7\alpha,11\alpha$))-.

Claim 82 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, methyl ester, ($6\alpha,7\alpha,11\alpha,17\alpha$)-.

Claim 83 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, monopotassium salt, ($6\alpha,7\alpha,11\alpha,17\alpha$)-.

Claim 84 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is 3'H-cyclopropa[6,7]pregna-4,6-diene-21-carboxylic acid, 9,11-epoxy-6,7-dihydro-17-hydroxy-3-oxo-, (-lactone, ($6\alpha,7\alpha,11\alpha,17\alpha$))-.

Claim 85 (withdrawn) The method of claim 75 wherein said aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, (-lactone, ethyl ester, ($7\alpha,11\alpha,17\alpha$))-.

Claim 86 (withdrawn) The method of claim 75 wherein said Aldosterone receptor antagonist is Pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-

hydroxy-3-oxo-, (-lactone, ethyl ester, (7 α ,11 α ,17 α)-.

Claim 87-90 (canceled)

Claim 91 (Previously presented) The method of Claim 75 wherein the therapeutically-effective amount of epoxy-steroidal compound administered is between about 0.5 to about 10 mg per day.

Claim 92-95 (canceled)

Claim 96 (Previously presented) The method of Claim 76 wherein the therapeutically-effective amount of epoxy-steroidal compound administered is between about 0.5 to about 10 mg per day.